Khiron CEO Alvaro Torres to Present at AltaCorp/ATB 8th Annual Institutional Investor ConferenceHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Khiron CEO Alvaro Torres to Present at AltaCorp/ATB 8th Annual Institutional Investor ConferenceCNW GroupJanuary 6, 2020ReblogShareTweetShareTORONTO , Jan. 6, 2020 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , today announced that CEO and Director Alvaro Torres will speak on the International Expansion panel at the AltaCorp/ATB 8th Annual Institutional Investor Conference at 3:10pm on January 14, 2020 . Mr. Torres and other members of the Khiron leadership team will also be conducting one-on-one meetings at the conference, taking place January 14-16, 2020 at the Shangri-La Hotel Toronto.View photosKhiron Life Sciences Corp. (CNW Group/Khiron Life Sciences Corp.)MoreIn addition to Khiron, the AltaCorp/ATB Conference Life Sciences Day on January 14 will also feature select companies across the cannabis sector value chain, including cannabinoid-derived pharmaceuticals, biosynthetics, extraction, as well as leading brands in the recreational, medical and retail markets.About Khiron Life Sciences Corp.Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America . Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres , together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico , Vicente Fox . Cautionary NotesForward-Looking StatementsThis press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.Story continuesUnited States DisclaimerThis news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.Further information in respect of the Company can be found at www.khiron.ca.CisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/khiron-ceo-alvaro-torres-to-present-at-altacorpatb-8th-annual-institutional-investor-conference-300981312.htmlSOURCE Khiron Life Sciences Corp.View photosView original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2020/06/c8739.htmlReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextLatin America roundup: SoftBank adds $1B, Stori raises $10M and Grow Mobility puts on the brakesTechCrunch‘El Chapo’ Producer Exile & Endeavor Content Ink First-Look Deal With ‘Time Share’ Director Sebastian HofmannDeadlineToronto Stock Exchange Gets ‘Black Eye,’ Closes Early In RoutBloombergBrazil: coronavirus worry emerges with new suspected casesAssociated PressLatin American leaders used state repression against protests: AmnestyAFPRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo Finance